{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-038400","form_type":"8-K","ticker":"PPCB","cik":"0001517681","company_name":"Propanc Biopharma, Inc.","filed_at":"2023-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.343110+00:00","generated_at":"2026-06-09T08:29:39.789507+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Propanc Biopharma issues $40K convertible note to 1800 Diagonal Lending","bullets":["Principal $40,000, convertible at 65% of lowest three trading prices in prior ten trading days.","Interest 8% per annum (22% on default); maturity October 20, 2024.","Company may prepay at 110%-129% premium within first 180 days; no prepayment after that.","Proceeds used for general working capital; funds not yet received as of filing date.","Conversion subject to 4.99% beneficial ownership limitation; 500% initial share reserve required."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-038400","json":"https://secwatch.observer/filing/0001493152-23-038400.json","markdown":"https://secwatch.observer/filing/0001493152-23-038400.md","text":"https://secwatch.observer/filing/0001493152-23-038400.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223038400/0001493152-23-038400-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223038400/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T08:29:39.789507+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bb8bed45acfef320f7196120a990b7c8e053c04c","claim":"Propanc Biopharma, Inc. incurred convertible notes of $40,000 with an investor at 8% per annum, which may be increased to 22% in the event of a default maturing October 20, 2024.","evidence_excerpt":"On October 20, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $40,000","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223038400/0001493152-23-038400-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$40,000"},{"label":"Counterparty","value":"an investor"},{"label":"Rate","value":"8% per annum, which may be increased to 22% in the event of a default"},{"label":"Maturity","value":"October 20, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"ed01d3dabd6e5fb9cf5c5cbe13001ffe3807e35b","claim":"Propanc Biopharma, Inc. entered into Purchase Agreement with an investor (the \"Investor\") valued at $40,000 (effective 2023-10-20).","evidence_excerpt":"On October 20, 2023, Propanc Biopharma, Inc. (the \"Company\") entered into a securities purchase agreement (the \"Purchase Agreement\") with an investor (the \"Investor\"), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $40,000 (the \"Note\")","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223038400/0001493152-23-038400-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an investor (the \"Investor\")"},{"label":"Value","value":"$40,000"},{"label":"Effective","value":"2023-10-20"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}